Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sapient Discovery Collaborates With Helicon Therapeutics
As per the terms of the agreement, Sapient Discovery is expected to apply its proprietary structural biology platform and expertise to determine the three-dimensional structures for targets of
As per the terms of the agreement, Sapient Discovery is expected to apply its proprietary structural biology platform and expertise to determine the three-dimensional structures for targets of
Pieris said that the trial is designed to test PRS-050 in approximately 40 patients, who will receive the compound and then be monitored for safety and tolerability. The
Currently CDI has validated a panel of cell-based cytotoxicity assays from Promega that use CDI’s human induced pluripotent stem (iPS) cell-derived iCell Cardiomyocytes. CDI and its pharmaceutical collaborators
BioClinica, a corporate sponsor of the MCC, is an open, collaborative organization dedicated to promote the development of performance metrics for both sponsors and service providers in support
According to the NeoStem, the two production lines produced the materials for over 70% of Erye’s product sales in 2009. Coupled with the approval of the lines earlier
Cytokine results of the dose-finding study in pregnant women at term gestation confirmed the efficacy and safety of its investigational product and suggested that the MVI may reduce
Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings. As per the agreement, Norgine is expected to make an upfront
Cairo-based Minapharm is a manufacturer and marketer of specialty pharmaceuticals and, through its subsidiary Rhein Minapharm Biogenetics, is in the research, development and manufacturing of biopharmaceuticals. ProBioGen will
Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated
In 2006, Mr Grant began his tenure as Allergan’s corporate vice president and president. Prior to that he has served as acting chairman, president and CEO of Biolase